GlassScriptPhysician profile
Penelope Ostarly
NPI 1184204216
$7,566.41
in general payments reported to CMS, 2019-2025
22 companies · $2,707 in 2025
The $2,707 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,764 · 2023: $1,902 · 2024: $1,193 · 2025: $2,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,172 · Travel and Lodging: $1,603 · Entertainment: $26.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,172.43 |
| Travel and Lodging | $1,603.37 |
| Entertainment | $26.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,112.55 | 2022-2025 | Intracept, General - Pain Management, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $1,406.07 | 2022-2025 | Synchromedii, Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $695.35 | 2022-2025 | Xtampza, Belbuca |
| Relievant Medsystems, INC. | $671.31 | 2022-2023 | Intracept |
| Abbott Laboratories | $256.43 | 2022-2023 | Eterna, Proclaim |
| Abbvie INC. | $246.67 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $232.04 | 2025 | |
| Scilex Pharmaceuticals INC. | $171.64 | 2024 | |
| Stryker Corporation | $156.21 | 2025 | Mild Device Kit, Multigen 2 |
| Curonix LLC | $107.59 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Tersera Therapeutics LLC | $89.50 | 2025 | Prialt |
| Averitas Pharma INC. | $83.12 | 2024-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.94 | 2022-2025 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $52.11 | 2022 | |
| Mml US, INC. | $51.83 | 2025 | Reactiv8 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $40.75 | 2025 | Zilretta, Iovera |
| Almatica Pharma LLC | $36.03 | 2023 | Gralise |
| Foundation Fusion Solutions, LLC | $26.59 | 2025 | |
| Amgen INC. | $18.64 | 2022 | |
| Stimwave Technologies Incorporated | $16.83 | 2022 | |
| Valinor Pharma, LLC | $15.65 | 2024 | Movantik |
| Nevro Corp. | $15.56 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penelope Ostarly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.